12:00 AM
 | 
Jan 04, 2010
 |  BC Week In Review  |  Company News  |  Deals

Ligand, Neurogen deal

Ligand completed its previously announced acquisition of Neurogen in a stock deal valued at $8.9 million based on 4.2 million shares issued and Ligand's close...

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >